The most important technological shifts rarely arrive with ceremonies or consensus. They become infrastructure first, and history later. Artificial intelligence is now undergoing that kind of transition—quietly reshaping coordination, decision-making and medicine while public debate remains fixated on milestones and definitions that lag reality.
Artificial intelligence has not solved drug discovery. It has exposed where pharmaceutical development really fails. As decision-making replaces invention as the bottleneck, Western drugmakers are quietly reorganising pipelines and partnerships pulling China into the system not by admiration, but by necessity.
Britain has accepted a trade linked medicines pricing reset that makes the NHS pay more. NICE’s new chief executive has warned that paying more to satisfy Trump style demands is a huge backwards step because higher drug spend means higher taxes or NHS cuts. This analysis explains what the government agreed, why the policy is fracturing, and how the NHS cost can be estimated.